JP7699107B2 - 操作されたリパーゼ改変体 - Google Patents

操作されたリパーゼ改変体 Download PDF

Info

Publication number
JP7699107B2
JP7699107B2 JP2022513058A JP2022513058A JP7699107B2 JP 7699107 B2 JP7699107 B2 JP 7699107B2 JP 2022513058 A JP2022513058 A JP 2022513058A JP 2022513058 A JP2022513058 A JP 2022513058A JP 7699107 B2 JP7699107 B2 JP 7699107B2
Authority
JP
Japan
Prior art keywords
lipase
sequence
seq
recombinant
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022513058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545718A (ja
Inventor
チンピン チェン，
ウィリアム ケイシー ハロウズ，
ジュディ ヴィクトリア アントニオ ヴィドゥヤ，
ニッキ デラス，
ステファニー スー ガラニー，
クリステン ジーン ヴァリュウ，
Original Assignee
ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ・デ・プロデュイ・ネスレ・エス・アー filed Critical ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Publication of JP2022545718A publication Critical patent/JP2022545718A/ja
Priority to JP2025061960A priority Critical patent/JP2025121900A/ja
Application granted granted Critical
Publication of JP7699107B2 publication Critical patent/JP7699107B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022513058A 2019-08-30 2020-08-28 操作されたリパーゼ改変体 Active JP7699107B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061960A JP2025121900A (ja) 2019-08-30 2025-04-03 操作されたリパーゼ改変体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962894019P 2019-08-30 2019-08-30
US62/894,019 2019-08-30
PCT/US2020/048405 WO2021041809A1 (en) 2019-08-30 2020-08-28 Engineered lipase variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061960A Division JP2025121900A (ja) 2019-08-30 2025-04-03 操作されたリパーゼ改変体

Publications (2)

Publication Number Publication Date
JP2022545718A JP2022545718A (ja) 2022-10-28
JP7699107B2 true JP7699107B2 (ja) 2025-06-26

Family

ID=74680918

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513058A Active JP7699107B2 (ja) 2019-08-30 2020-08-28 操作されたリパーゼ改変体
JP2025061960A Pending JP2025121900A (ja) 2019-08-30 2025-04-03 操作されたリパーゼ改変体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061960A Pending JP2025121900A (ja) 2019-08-30 2025-04-03 操作されたリパーゼ改変体

Country Status (12)

Country Link
US (2) US11987823B2 (enExample)
EP (2) EP4022049B1 (enExample)
JP (2) JP7699107B2 (enExample)
KR (1) KR20220106738A (enExample)
CN (2) CN115175995B (enExample)
AU (1) AU2020336468B2 (enExample)
BR (1) BR112022003705A2 (enExample)
CA (1) CA3152763A1 (enExample)
ES (1) ES3007439T3 (enExample)
IL (1) IL290978A (enExample)
MX (1) MX2022002473A (enExample)
WO (1) WO2021041809A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102897514B1 (ko) * 2022-03-31 2025-12-08 동아대학교 산학협력단 꿀벌 유래 지질분해 효소 및 이의 용도
CN118185905B (zh) * 2024-05-20 2024-07-26 中国海洋大学 脂肪酶Lip1897-H106W及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524421A (ja) 2000-02-24 2003-08-19 アルタス バイオロジックス インコーポレイテッド リパーゼ含有組成物およびこれらの使用方法
JP2019089781A (ja) 2009-01-06 2019-06-13 ガレナゲン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59169891A (ja) 1983-03-16 1984-09-25 Konishiroku Photo Ind Co Ltd 光学的情報記録媒体の製造方法
SE9001985D0 (sv) 1990-06-01 1990-06-01 Astra Ab New chemical products
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
ATE294871T1 (de) 1994-06-30 2005-05-15 Novozymes Biotech Inc Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
FR2733249B1 (fr) * 1995-04-20 1997-06-06 Biocem Lipase gastrique de chien recombinante et polypeptides derives produits par les plantes, leurs procedes d'obtention et leurs utilisations
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP1717322B1 (en) 1997-01-17 2012-07-18 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
WO1998031816A1 (en) 1997-01-17 1998-07-23 Regents Of The University Of Minnesota Dna molecules and protein displaying improved triazine compound degrading ability
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
CA2326835A1 (en) 1998-04-02 1999-10-14 Tellus Genetic Resources, Inc. A method for obtaining a plant with a genetic lesion in a gene sequence
CN1314911A (zh) 1998-05-01 2001-09-26 麦克西根股份有限公司 用dna改组优化害虫抗性基因
JP2002517995A (ja) 1998-06-17 2002-06-25 マキシジェン， インコーポレイテッド 所望の特性を有するポリヌクレオチドを生成するための方法
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
EP1104459A1 (en) 1998-08-12 2001-06-06 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
AU6510799A (en) 1998-10-07 2000-04-26 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
EP1129184A1 (en) 1998-11-10 2001-09-05 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
JP2002534965A (ja) 1999-01-19 2002-10-22 マキシジェン， インコーポレイテッド 所望の特徴を有する文字ストリング、ポリヌクレオチドおよびポリペプチドを作製するための方法
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
IL144657A0 (en) 1999-02-11 2002-06-30 Maxygen Inc High throughput mass spectrometry
AU3391900A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
SG121902A1 (en) 2000-01-11 2006-05-26 Maxygen Inc Integrated systems for diversity generation and screening
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
AU2001249811B2 (en) 2000-04-03 2006-06-08 Maxygen, Inc. Subtilisin variants
US6858422B2 (en) 2000-07-13 2005-02-22 Codexis, Inc. Lipase genes
US6862271B2 (en) 2002-02-26 2005-03-01 Qualcomm Incorporated Multiple-input, multiple-output (MIMO) systems with multiple transmission modes
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
EP2315145B1 (en) 2002-03-01 2015-11-25 Codexis Mayflower Holdings, LLC Methods, systems, and software for identifying functional biomolecules
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
US7020762B2 (en) 2002-12-24 2006-03-28 Intel Corporation Method and apparatus for determining a dynamic random access memory page management implementation
US7303904B2 (en) * 2003-01-30 2007-12-04 Council Of Scientific & Industrial Research Stable gene variants of lipases
CA2515583C (en) 2003-03-07 2015-07-14 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for making and using them
US7629157B2 (en) 2003-08-11 2009-12-08 Codexis, Inc. Ketoreductase polypeptides and related polynucleotides
DK1809320T3 (da) 2004-10-14 2010-11-15 Cystic Fibrosis Foundation The Præparater indeholdende lipase, protease og amylase til behandling af pankreatisk insufficiens
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
KR101497159B1 (ko) 2006-06-15 2015-03-03 라보라뜨와르 메이올리 스핀들러 리파아제 생산 방법, 상기 리파아제를 생산할 수 있는 형질전환된 Ｙａｒｒｏｗｉａ ｌｉｐｏｌｙｔｉｃａ 세포 및 그 용도
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2009102901A1 (en) 2008-02-12 2009-08-20 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
ES2705694T3 (es) 2008-06-13 2019-03-26 Codexis Inc Método de síntesis de variantes de polinucleótidos
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
BRPI0922653B8 (pt) 2009-01-29 2021-05-25 Nordmark Arzneimittel Gmbh & Co Kg uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa
WO2013003290A1 (en) 2011-06-28 2013-01-03 Codexis, Inc. Protein variant generation by region shuffling
EP4062928A3 (en) 2010-02-04 2022-11-30 BioMarin Pharmaceutical Inc. Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia
MY171837A (en) * 2010-09-14 2019-11-01 Univ Putra Malaysia Novel microorganisms producing thermostable lipase from oil contaminated sample and methods thereof
US20150133698A1 (en) 2012-04-20 2015-05-14 Codexis, Inc. Production of fatty alcohols from engineered microorganisms
WO2013170050A1 (en) 2012-05-11 2013-11-14 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
AU2013316124C1 (en) 2012-09-14 2022-01-06 Genomatica, Inc. Enzyme variants with improved ester synthase properties
RU2695146C2 (ru) 2013-01-31 2019-07-22 Кодексис, Инк. Способы, системы и программное обеспечение для идентификации биомолекул со взаимодействующими компонентами
CA2970638A1 (en) 2014-12-22 2016-06-30 Codexis, Inc. Human alpha-galactosidase variants
US9821613B2 (en) 2015-07-20 2017-11-21 Bendix Commercial Vehicle Systems Llc Transmitting device with antenna
DE102015114859A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Verwendung einer pharmazeutischen Zusammensetzung, enthaltend mindestens ein Verdauungsenzym, bei der künstlichen Ernährung
WO2017131927A1 (en) 2016-01-26 2017-08-03 Applied Materials, Inc. Wafer edge ring lifting solution
JP2020530267A (ja) 2017-06-30 2020-10-22 コデクシス， インコーポレイテッド Ｔ７ ｒｎａポリメラーゼバリアント
WO2019185612A1 (en) 2018-03-26 2019-10-03 Basf Se Method of reducing soil water repellency

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524421A (ja) 2000-02-24 2003-08-19 アルタス バイオロジックス インコーポレイテッド リパーゼ含有組成物およびこれらの使用方法
JP2019089781A (ja) 2009-01-06 2019-06-13 ガレナゲン リミテッド ライアビリティ カンパニー 大腸菌（Ｅ．ｃｏｌｉ）による経口感染の治療または予防のための組成物および方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Database DDBJ/EMBL/GenBank [online]，Accession no. WP_034771740, DEFINITION: lipase [Caldibacillus thermoamylovorans]，インターネット <URL: https://www.ncbi.nlm.nih.gov/protein/736768283?sat=58&satkey=92312624>，23-DEC-2014 [検索日 2024.8.5]
Database DDBJ/EMBL/GenBank [online]，Accession no. WP_041845597, DEFINITION: lipase [Caldibacillus thermoamylovorans]，インターネット <URL: https://www.ncbi.nlm.nih.gov/protein/754285792?sat=58&satkey=137721777>，06-FEB-2015 uploaded [検索日 2024.8.5]
Database DDBJ/EMBL/GenBank [online]，Accession no. WP_108898452, DEFINITION: lipase [Caldibacillus thermoamylovorans]，インターネット <URL:https://www.ncbi.nlm.nih.gov/protein/1388010833?sat=58&satkey=136424929>，09-MAY-2018 [検索日 2024.8.5]

Also Published As

Publication number Publication date
JP2025121900A (ja) 2025-08-20
IL290978A (en) 2022-05-01
BR112022003705A2 (pt) 2022-05-24
EP4022049B1 (en) 2025-01-08
US20240263156A1 (en) 2024-08-08
CN119506248A (zh) 2025-02-25
MX2022002473A (es) 2022-08-02
ES3007439T3 (en) 2025-03-20
CN115175995B (zh) 2025-05-02
EP4501403A2 (en) 2025-02-05
US12680091B2 (en) 2026-07-14
US20210062168A1 (en) 2021-03-04
CA3152763A1 (en) 2021-03-04
EP4501403A3 (en) 2025-05-14
JP2022545718A (ja) 2022-10-28
AU2020336468B2 (en) 2026-04-02
AU2020336468A1 (en) 2022-03-03
EP4022049A1 (en) 2022-07-06
EP4022049A4 (en) 2023-11-01
WO2021041809A1 (en) 2021-03-04
US11987823B2 (en) 2024-05-21
CN115175995A (zh) 2022-10-11
KR20220106738A (ko) 2022-07-29

Similar Documents

Publication Publication Date Title
JP2025121900A (ja) 操作されたリパーゼ改変体
JP2022103296A (ja) フェニルアラニンアンモニアリアーゼポリペプチド
US12502421B2 (en) Engineered leucine decarboxylases
US20240384251A1 (en) Engineered amylase variants
KR20220137057A (ko) 조작된 류신 데카르복실라제
US11959108B2 (en) Engineered protease variants
US20220389464A1 (en) Engineered tyrosine ammonia lyase
RU2844866C1 (ru) Сконструированные варианты липаз
WO2023154879A2 (en) Engineered oxalate decarboxylases
HK40077280B (en) Engineered lipase variants
HK40077280A (en) Engineered lipase variants
TW202313969A (zh) 經工程化的甲硫胺酸γ解離酶變異體
CN117413057A (zh) 工程化甲硫氨酸γ裂合酶变体
EA050437B1 (ru) Сконструированные лейциндекарбоксилазы

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230825

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240510

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240510

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250616

R150 Certificate of patent or registration of utility model

Ref document number: 7699107

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150